• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Regeneron touts possible 'best-in-class' myeloma bispecific, but adverse events...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 07, 2023 at 11:53: AM
via All patients reported at least one adverse event and 14 deaths occurred "due to treatment-emergent" adverse events in the early-stage trial. Regeneron posted the results Thursday ahead of this weekend's American Society of Hematology's annual meeting.

article source
 




Top Bottom
Back
Quote